Related Experiment Video
Updated: Dec 5, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Linezolid-induced thrombocytopenia in a child with a liver transplant: A case report
Insights
Linezolid can cause low platelets (thrombocytopenia) in children after liver transplants. This risk is higher due to linezolid concentrating in the liver, especially in Asian populations.
Area of Science:
- Pharmacology
- Transplant Hepatology
- Pediatric Infectious Diseases
Background:
- Linezolid is an antibiotic used for serious infections.
- Thrombocytopenia is a known side effect of linezolid.
- Liver transplant patients, particularly children, are a vulnerable population.
Observation:
- A 7-month-old liver transplant recipient developed linezolid-induced thrombocytopenia.
- Physiologically based pharmacokinetic (PBPK) modeling indicated high linezolid distribution in the liver.
- Asian patients may have altered linezolid pharmacokinetics (PK) compared to Caucasians, potentially increasing adverse effects.
Findings:
- Linezolid demonstrates significant distribution within the liver.
- Lower body weight in Asian populations correlates with lower clearance and higher Cmax of linezolid.
- This suggests a heightened risk of linezolid-induced thrombocytopenia in liver injury patients, especially children of Asian ethnicity.
Implications:
- Clinicians should exercise increased vigilance for linezolid-induced thrombocytopenia in liver transplant patients.
- Consideration of patient ethnicity and body weight is crucial for optimizing linezolid dosing and minimizing adverse events.
- Further research into ethnic PK differences may refine antibiotic use in pediatric liver transplant recipients.
Objective:
Linezolid-induced thrombocytopenia is rarely reported in liver transplant patients, especially in children.
Case Summary:
We report a case of a 7-month-old liver-transplanted child who suffered from thrombocytopenia induced by linezolid. We simulated the pharmacokinetics of linezolid in a healthy adult using the physiologically based pharmacokinetic (PBPK) model and found that the liver is the most abundant organ for the distribution of linezolid.
Practice Implications:
Linezolid has a high distribution in the liver. As a result, an increased awareness about the risk of linezolid-induced thrombocytopenia should be strengthened in patients with liver injury. Effects of ethnicity: The differences between Chinese patients and patients of other ethnicities may lead to the diverse effects of linezolid in different patients. The influence of body weight (BW) difference in pharmacokinetics (PK) of linezolid between Asian (Chinese and Japanese) and Caucasians was demonstrated in several population PK studies [1, 2, 3]. The average BW of Asians is lower than that of the Caucasian population, the clearance and apparent volume of distribution are lower than in the European population, and Cmax is higher than in the Western population. Therefore, the adverse effects of linezolid at the same dose may increase in Chinese patients.
